{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:28:58Z","timestamp":1777328938152,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.canlet.2007.12.003","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T17:14:41Z","timestamp":1200503681000},"page":"232-238","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer"],"prefix":"10.1016","volume":"262","author":[{"given":"Louis Wing-Cheong","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Yun-San","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wings Tjing-Yung","family":"Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2007.12.003_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2007.12.003_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2007.12.003_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/1096-9098(200011)75:3<172::AID-JSO4>3.0.CO;2-A","article-title":"Hormonal receptor determination of 1052 Chinese breast cancers","volume":"75","author":"Chow","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.canlet.2007.12.003_bib4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/14656566.3.9.1329","article-title":"Anastrozole in the management of breast cancer","volume":"3","author":"Nabholtz","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2007.12.003_bib5","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1210\/en.137.7.3061","article-title":"Expression of aromatase protein and messenger ribonucleotide acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers","volume":"137","author":"Lu","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2007.12.003_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1056\/NEJM200101253440407","article-title":"Estrogen and the risk of breast cancer","volume":"344","author":"Clemons","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.12.003_bib7","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.12.003_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/35035131","article-title":"Interaction of oestrogen receptor with the regulatory with the regulatory subunit of phosphatidylinositol-3-OH kinase","volume":"407","author":"Simoncini","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.canlet.2007.12.003_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/me.13.5.787","article-title":"Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo","author":"Lee","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2007.12.003_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/me.9.4.443","article-title":"Tamoxifen activation of the estrogen receptor\/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens","volume":"9","author":"Webb","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2007.12.003_bib11","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1128\/MCB.20.14.5041-5047.2000","article-title":"AIB1 is a conduit for kinase-mediated growth factor signaling to estrogen receptor","volume":"20","author":"Font de Mora","year":"2000","journal-title":"Mol. cell. Biol."},{"key":"10.1016\/j.canlet.2007.12.003_bib12","first-page":"3766s","article-title":"ZD1839 (Iressa) improves the antitumor activity of tamoxifen in anti-hormone-responsive breast cancer cells","volume":"7","author":"Nicholson","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2007.12.003_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"7","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2007.12.003_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2007.12.003_bib15","first-page":"292","article-title":"Assessment of response of therapy in advanced breast cancer","volume":"3","author":"Hayward","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2007.12.003_bib16","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. Available from: <http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf> [December, 12 2003]."},{"key":"10.1016\/j.canlet.2007.12.003_bib17","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1517\/14656566.7.14.1919","article-title":"Update on the use of aromatase inhibitors in breast cancer","volume":"7","author":"Brueggemeier","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2007.12.003_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7800-3-31","article-title":"Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update","volume":"3","author":"Mokbel","year":"2006","journal-title":"Int. Semin. Surg. Oncol."},{"key":"10.1016\/j.canlet.2007.12.003_bib19","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.12.003_bib20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2007.12.003_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.12.003_bib22","doi-asserted-by":"crossref","unstructured":"ATAC Trialists\u2019 Group, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer, Lancet. 365 (2005) 60\u201362.","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"10.1016\/j.canlet.2007.12.003_bib23","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signalling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2007.12.003_bib24","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1158\/1078-0432.CCR-06-1535","article-title":"Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches","volume":"12","author":"Moy","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2007.12.003_bib25","first-page":"S240","article-title":"Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer","volume":"94","author":"Chow","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2007.12.003_bib26","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0959-8049(02)80608-6","article-title":"Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"38","author":"van Oosterom","year":"2002","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.canlet.2007.12.003_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1445-5994.2006.01077.x","article-title":"Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach","volume":"36","author":"Harrison","year":"2006","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.canlet.2007.12.003_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438350700599X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438350700599X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:30:31Z","timestamp":1557189031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438350700599X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S030438350700599X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2007.12.003","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}